Metopimazine Sans Sucre,édulcoré À L’aspartam Medipha

Metopimazine, the active ingredient in Metopimazine Sans Sucre, édulcoré À L’aspartam Medipha, is a phenothiazine antiemetic presented as an oral tablet for systemic use. It is employed to control nausea and vomiting, including post‑operative and chemotherapy‑induced episodes, and improves overall comfort during treatment.

GNH USA supplies Metopimazine Sans Sucre, édulcoré À L’aspartam Medipha as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance and timely delivery.

Metopimazine is a phenothiazine antiemetic that acts on the chemoreceptor trigger zone to reduce nausea and vomiting. - Nausea and vomiting: Provides symptomatic relief of acute and chronic nausea and vomiting in adult patients. - Post‑operative nausea: Reduces incidence and severity of nausea following surgical procedures. - Chemotherapy‑induced nausea: Controls nausea and vomiting associated with cytotoxic chemotherapy.

Metopimazine may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Drowsiness: Feeling of sleepiness or reduced alertness. - Dry mouth: Reduced salivation leading to a dry oral cavity. - Constipation: Decreased bowel movements or difficulty passing stool. - Dizziness: Light‑headed sensation, especially when standing quickly. - Blurred vision: Temporary visual disturbance. Serious or Rare Side Effects: - Extrapyramidal symptoms: Involuntary muscle movements or rigidity. - Neuroleptic malignant syndrome: Rare life‑threatening reaction with fever and muscle rigidity. - Cardiac arrhythmias: Abnormal heart rhythm, potentially serious. - Severe hypotension: Marked drop in blood pressure causing faintness.

When prescribing Metopimazine, clinicians should consider several safety precautions. - Assess patient history: Review for prior extrapyramidal reactions or Parkinsonian symptoms. - Monitor cardiovascular status: Observe for hypotension or arrhythmias, especially in patients with cardiac disease. - Caution in the elderly: Increased sensitivity to sedation and anticholinergic effects. - Avoid concurrent CNS depressants: Limit use with alcohol, opioids, or other sedatives. - Pregnancy and lactation: Use only if the potential benefit outweighs the risk, as safety data are limited. - Store at ambient temperature: Keep below 25 °C in the original packaging, protect from moisture.

Metopimazine can interact with other medicines, altering its efficacy or safety. Major Interactions (Avoid): - Antipsychotics: Combined dopamine antagonism may increase extrapyramidal risk. - QT‑prolonging agents: Additive effect on cardiac repolarization, raising arrhythmia risk. Moderate Interactions (Monitor Closely): - CNS depressants: Enhanced sedation when used with alcohol, opioids, or benzodiazepines. - Anticholinergic drugs: May worsen dry mouth and constipation. - MAO inhibitors: Potential for hypertensive reactions; avoid concurrent use. - CYP2D6 substrates: Metopimazine may inhibit metabolism, requiring dose adjustment of affected drugs.